Proactive Investors - Run By Investors For Investors

Novavax shares surge following positive Phase 2 trial of flu vaccine

The clinical-stage biotech plans to meet with the FDA in the first half of the year to discuss the Phase 2 clinical trial results
Scientist sitting and looking into a microscope
Phase 3 clinical trials are expected to begin this year

Novavax Inc (NASDAQ:NVAX) shares were on the rise after the company announced positive Phase 2 trial results for its NanoFlu vaccine.

The clinical-stage biotech plans to meet with the US Food and Drug Administration in the first half of the year to discuss the Phase 2 clinical trial results and expects Phase 3 clinical trials to begin this year.

READ: AngioDynamics fiscal 2Q results boosted by oncology sales

Shares of Novavax jumped more than 7% to $2.19 in Friday pre-market trading.

“Over the past several years, influenza vaccine effectiveness has been suboptimal in this population, and there is broad agreement that better vaccines are needed,” said Gregory Glenn, president of research and development.

“These confirmatory data from the second clinical trial of NanoFlu further justify continued rapid development of an improved vaccine,” he added.

The company estimated that seasonal flu vaccine growth in the top seven markets, which include the US, Japan, France, Germany, Italy, Spain and UK, may increase from around $3.2 billion in 2015 to $5.3 billion by 2021.

 

Contact Lenore Fedow at [email protected]

Follow her on Twitter@LenoreMariee

View full NVAX profile View Profile

Novavax Timeline

Related Articles

Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
patch
May 19 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use